“Drug Watch” Sent Back To The Drawing Board; FDA Turning To MedWatch?
This article was originally published in The Tan Sheet
Executive Summary
FDA is considering proactive communication of early adverse event reports from its MedWatch monitoring system as the agency reassesses its proposed Drug Watch website for emerging safety information
You may also be interested in...
“MedWatch Plus” Will Create Single Adverse Event Reporting Venue
FDA's vision for a revamped MedWatch system includes a single portal for adverse event submissions from a variety of sources
“MedWatch Plus” Will Create Single Adverse Event Reporting Venue
FDA's vision for a revamped MedWatch system includes a single portal for adverse event submissions from a variety of sources
“MedWatch Plus” Will Create Single Adverse Event Reporting Venue
FDA's vision for a revamped MedWatch system includes a single portal for adverse event submissions from a variety of sources